Pricing Index · Updated September 1, 2026

Mounjaro Cost in 2026: Brand vs Compounded Tirzepatide

Eli Lilly's list price for Mounjaro is about $1,023/mo cash-pay. Most patients pay much less. Below is the full picture: Lilly Direct, savings programs, branded telehealth ($69 to $1069/mo), and compounded tirzepatide ($99.6 to $600/mo).

1. Eli Lilly direct pricing

In 2024 Eli Lilly launched Lilly Direct, a self-pay vial program for tirzepatide. As of September 2026, those vials are sold under the Zepbound label, Zepbound's FDA-approved indication (chronic weight management), not the Mounjaro label:

• 2.5 mg vial: $299/mo
• 5 mg vial: $399/mo
• 7.5 mg through 15 mg: $449/mo, provided you refill within 45 days of your last delivery

The vials require you to draw and inject yourself with a syringe, which is one reason some patients still prefer the pens. Because Lilly Direct's discounted vial program is Zepbound-branded, cash-pay Mounjaro pens (the diabetes-indicated product) still transact near list price. If you have commercial insurance that covers Mounjaro for type 2 diabetes, the separate Mounjaro savings card (different from Lilly Direct) brings eligible patients to about $25/mo for the auto-injector pens, capped at $150/month savings ($1,950/year).

2. Branded tirzepatide programs we track

We track 29 telehealth and clinic programs offering branded tirzepatide (Mounjaro or Lilly Direct). Sorted by monthly cost:

See the full pricing index for methodology and CSV download.

3. Compounded tirzepatide alternative

Some providers advertise compounded tirzepatide at lower prices. These products are not FDA-approved, are not generic Mounjaro, and have not been reviewed by FDA for safety, effectiveness, quality, or bioequivalence. We track 54 advertised programs:

The tirzepatide shortage ended in October 2024, so the broad shortage-based path for routine copies ended after the enforcement grace periods. Limited patient-specific compounding may occur only when federal and state requirements are met. Read our guide on brand vs compounded for the full picture.

4. Mounjaro dosing cost ladder

Brand-name Mounjaro pen pricing scales with dose volume rather than dose strength. The list price of about $1,023/mo applies to all six doses (2.5, 5, 7.5, 10, 12.5, 15 mg). Lilly Direct's self-pay vials cover the same six doses, but only under the Zepbound label.

If you titrate to 7.5 mg or higher and want to keep cash-pay costs down, your options are:

• Compounded tirzepatide at the equivalent dose
• Switching to Zepbound (FDA-approved for obesity, sometimes covered by insurance, and the only tirzepatide brand sold as a self-pay vial)
• Manufacturer savings card if you have commercial insurance that covers Mounjaro

5. Insurance and savings programs

Mounjaro is FDA-approved for type 2 diabetes only. Off-label weight-loss prescriptions are usually denied by commercial insurers. Two paths:

1. Diagnosis-based coverage: if you have type 2 diabetes or A1C above 6.5, your plan likely covers Mounjaro at a copay between $25 and $200/mo.
2. Mounjaro savings card: commercial-insurance patients pay as little as $25/mo for up to 13 fills per year. Federal-program patients (Medicare, Medicaid, VA) are excluded.

For weight-loss-only prescriptions, Zepbound (same molecule, different FDA indication) is more likely to be covered.

FAQ

How much does Mounjaro cost without insurance in 2026?

Eli Lilly's list price for Mounjaro is about $1,023/mo. Lilly's self-pay tirzepatide vials run $299 to $449/mo, but are dispensed under the Zepbound brand rather than Mounjaro. Branded tirzepatide telehealth programs in our index range $69 to $1069/mo, median $199/mo.

Is compounded tirzepatide cheaper than Mounjaro?

Yes. Compounded tirzepatide ranges $99.6 to $600/mo across 54 programs we track, median $279/mo. Roughly half to one third the cost of brand-name Mounjaro.

Does insurance cover Mounjaro for weight loss?

Most US insurers cover Mounjaro for type 2 diabetes (its FDA-approved use) but deny coverage for off-label weight loss. For weight loss specifically, Zepbound (same molecule, approved for obesity) has a higher chance of being covered if your plan has obesity-medication benefits.

What is the cheapest way to get Mounjaro in 2026?

Three options: the manufacturer savings card if you have commercial insurance that covers Mounjaro ($25/mo for eligible patients, capped at $150/month), Lilly Direct self-pay vials ($299 to $449/mo, though dispensed as Zepbound rather than Mounjaro), or compounded tirzepatide through a licensed telehealth provider ($99.6 to $600/mo).

Has Mounjaro been removed from the FDA shortage list?

Yes. The FDA declared the tirzepatide shortage resolved in October 2024. After a court-ordered grace period, 503A compounding pharmacies were instructed to wind down compounding by March 2025. Some providers continue under personalized-prescription doctrines, but the regulatory path is narrower than during the shortage period.

Sources

• Eli Lilly Direct pricing page (lilly.com/direct), reviewed September 2026
• Mounjaro savings card program terms (mounjaro.lilly.com/savings-coverage), reviewed September 2026
• FDA Drug Shortages database, tirzepatide injection status update (October 2024)

Related

• Mounjaro full medication profile
• Mounjaro vs Zepbound comparison
• Compounded tirzepatide profile
• Full GLP-1 pricing index
• Cheapest GLP-1 online